MindMed reports Phase 2b topline data for MM120 in GAD; gets FDA Breakthrough Therapy Designation

Definium Therapeutics, Inc.

Phase 2b trial of MM120 (LSD) for Generalized Anxiety Disorder: full topline data released on March 7, 2024.
FDA granted Breakthrough Therapy Designation for MM120 in GAD, accelerating development and review.
Company hosted conference call to discuss results and ODT PK bridging study data.
MM120 is a proprietary sublingual formulation of lysergide targeting anxiety disorders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.